Society guideline links: Pheochromocytoma and paraganglioma

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately.

●(See "Society guideline links: Diagnosis and treatment of Cushing syndrome".)

●(See "Society guideline links: Adrenal cancer".)

●(See "Society guideline links: Adrenal incidentaloma".)

●(See "Society guideline links: Neuroblastomas".)

International

●Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants (2023)

●Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants – An international expert consensus statement (2023)

●Consensus on molecular imaging and theranostics in neuroendocrine neoplasms (2021)

●International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers (2021)

●NGS in PPGL (NGSnPPGL) Study Group: Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas (2017)

Canada

●Hypertension Canada: Guidelines on Diagnosis & Assessment – Assessment for endocrine hypertension

●Hypertension Canada: Guidelines on Prevention & Treatment – Treatment of secondary hypertension due to endocrine causes

●Canadian Urological Association (CUA): Guideline for the diagnosis, management, and follow-up of the incidentally discovered adrenal mass (2023)

●North American Neuroendocrine Tumor Society (NANETS): Consensus guidelines for surveillance and management of metastatic and/or unresectable pheochromocytoma and paraganglioma (2021)

United States

●North American Neuroendocrine Tumor Society (NANETS): Consensus guidelines for surveillance and management of metastatic and/or unresectable pheochromocytoma and paraganglioma (2021)

●European Association of Nuclear Medicine (EANM)/Society of Nuclear Medicine and Molecular Imaging (SNMMI): Practice guideline/procedure standard for radionuclide imaging of phaeochromocytoma and paraganglioma (2019)

●Society of American Gastrointestinal and Endoscopic Surgeons (SAGES): Guidelines for the minimally invasive treatment of adrenal pathology (2013)

Europe

●European Society of Endocrinology (ESE) in collaboration with European Network for the Study of Adrenal Tumors (ENSAT): Clinical practice guideline on the management of adrenal incidentalomas (2023)

●European Society for Medical Oncology (ESMO) and European Network for Rare Adult Solid Cancers (EURACAN): Clinical practice guidelines for diagnosis, treatment and follow-up of adrenocortical carcinomas and malignant phaeochromocytomas (2020)

●European Society of Hypertension (ESH): A position statement and consensus on genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma (2020)

●European Association of Nuclear Medicine (EANM)/Society of Nuclear Medicine and Molecular Imaging (SNMMI): Practice guideline/procedure standard for radionuclide imaging of phaeochromocytoma and paraganglioma (2019)

●ESE: Clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma (2016)

United Kingdom

●British Skull Base Society (BSBS): Clinical consensus document on management of head and neck paragangliomas (2020)

●Clinical practice guidance – Surveillance for phaeochromocytoma and paraganglioma in paediatric succinate dehydrogenase gene mutation carriers (2018)

Japan

●[In Japanese] Japan Endocrine Society (JES): Clinical practice guideline of pheochromocytoma and paraganglioma (2018)